Optimized Chimeric Antigen Receptor T Cell Therapy for Colorectal Cancer

Colorectal cancer (CRC) is the third most common cancer in Minnesota, yet current treatments for advanced CRC have low survival rates. This project aims to develop a targeted cell therapy that enhances the killing of cancer cells and disrupts the tumor microenvironment. The researchers will further optimize this therapy in preclinical models, paving the way for a Phase I clinical trial to improve outcomes for CRC patients.